Salvatore Massimo Petrina: When is it Truly Safe to Stop Anticoagulation after AF Ablation?
Salvatore Massimo Petrina, Hospital Physician in Cardiology at the Provincial Health Authority of Ragusa, shared a post on LinkedIn about a recent article by Tomoya Iwawaki at al., published in JACC: Clinical Electrophysiology, adding:
“When is it truly safe to stop anticoagulation after AF ablation?
A new study in JACC: Clinical Electrophysiology (Iwawaki et al., 2026) offers an unexpected answer: timing matters more than simple ‘procedural success.’
What they did
They retrospectively analyzed 2,448 post-catheter ablation AF patients, comparing those who discontinued OACs with those who continued, evaluating 537 time points (landmark analysis with IPTW).
The key finding
The ‘reverse net clinical benefit’ (balance between bleeding and thromboembolic risk) peaks at 8.1 months post-ablation.
Here is the risk curve:
- Months 4–5: peak thromboembolic risk after discontinuation
- Beyond 6 months: bleeding risk progressively declines
- Nearly 8 months: the optimal balance point
The numbers at the 8.1-month landmark:
- Thromboembolism HR: 2.36 (p=0.010) → the risk is real and measurable
- Major bleeding HR: 0.18 (p=0.002) → the bleeding benefit is real
- Mortality: no significant difference
But watch the subgroups
Discontinuation is particularly risky in:
- Patients with asymptomatic AF (silent recurrences!)
- Patients with LVEF <60%
My take-away
This study is not a license to stop all OACs at 8 months ‘by the calendar.’
It is an elegant signal telling us: the decision is dynamic, not binary.
The 8.1-month optimum is population-level data, not a protocol to apply to everyone.
CHA₂DS₂-VASc stratification, post-ablation rhythm monitoring, and individual clinical status (especially LVEF and symptoms) remain the main compass.
Reflection:
How many of us have a structured conversation with the patient at 3–6–12 months post-ablation to reassess anticoagulant therapy, rather than leaving it as a ‘legacy’ from discharge?
Disclaimer:
This post is for educational and scientific update purposes only.
It does not constitute medical advice, therapeutic recommendation, or a substitute for individual clinical judgment.
Decisions on post-ablation anticoagulation must be made on a case-by-case basis, in accordance with current guidelines (ESC/AHA/ACC/HRS) and the individual patient’s embolic/bleeding risk assessment.”
Title: Optimal Timing for Oral Anticoagulant Discontinuation and Prognosis After Successful Catheter Ablation for Atrial Fibrillation
Authors: Tomoya Iwawaki, Satoshi Yanagisawa, Yasuya Inden, Kiichi Miyamae, Hiroyuki Miyazawa, Takayuki Goto, Shun Kondo, Masaya Tachi, Taishi Fukushima, Takehiro Hiramatsu, Kentaro Adachi, Tsubasa Teraoka, Ryusuke Ota, Masafumi Shimojo, Yukiomi Tsuji, Takahiro Okumura, Toyoaki Murohara
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering